33054 Improvement in touch avoidance in patients with genital psoriasis treated with ixekizumab: 52-week results of a phase 3 clinical trial in patients with moderate-to-severe genital psoriasis (IXORA-Q)

Abstract

Introduction: Genital psoriasis can have a significant impact on quality of life, where people may avoid close social interactions such as touching others or being touched. Ixekizumab, an interleukin 17A antagonist, demonstrated rapid and persistent improvement in genital psoriasis up to 52 weeks and touch avoidance (TA) up to 12 weeks. Here, we report TA up to 52 weeks with ixekizumab.